Bruker Corp Stock Price, News & Analysis

Bruker Corporation (Nasdaq: BRKR) reported Q3 2021 revenues of $608.9 million, a 19.1% increase year-over-year, with organic growth of 17.8%. GAAP EPS rose 63% to $0.57, while non-GAAP EPS increased 50% to $0.63. Operating income stood at $113.2 million with margins improving to 18.6%. For the first nine months, revenues totaled $1,734.4 million, an increase of 27.5%. The company raised its FY 2021 guidance, expecting revenue growth of 19.5%-20.5% and non-GAAP EPS between $2.05 and $2.09.

Bruker Corporation (Nasdaq: BRKR) will announce its third quarter 2021 financial results on November 1, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and current business trends. Investors can access the webcast at ir.bruker.com; a slide presentation will be available prior to the call. Pre-registration is encouraged to expedite entry. A replay will be available from one hour after the call until December 1, 2021.

Bruker Corporation (NASDAQ: BRKR) has received orders for two 1.1 GHz NMR Avance Neo systems from U.S. academic institutions, funded by the National Science Foundation. These systems will be used in the Network for Advanced NMR (NAN) consortium, linking the University of Connecticut, University of Wisconsin-Madison, and University of Georgia. The NAN aims to enhance research capabilities in life sciences and materials science through a hub-and-spoke model, allowing broader access to advanced NMR technology and training opportunities.

Bruker Corporation (Nasdaq: BRKR) will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 9:20 AM Eastern Time. Gerald Herman, Executive Vice President & CFO, and Falko Busse, President of the Bruker BioSpin Group, will engage in an analyst moderated Q&A session. Investors can access a live audio webcast and a 30-day replay via the Investor Relations section of Bruker's website. Bruker focuses on providing high-performance scientific instruments for advancements in life sciences and diagnostics.

Bruker Corporation (Nasdaq: BRKR) has declared a quarterly cash dividend of $0.04 per share on its common stock. This dividend is set to be paid on September 17, 2021, to stockholders of record by September 1, 2021. The company focuses on providing high-performance scientific instruments and analytical solutions that support innovations in life sciences, clinical diagnostics, and industrial applications, enhancing productivity and research success.

Bruker Corporation (Nasdaq: BRKR) reported strong financial results for Q2 and the first half of 2021, with Q2 revenues reaching $570.8 million, a 34.4% increase from Q2 2020. The organic revenue growth was 27.2%, driven by robust demand across its Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST) segments. GAAP diluted EPS for Q2 stood at $0.38, up from $0.16 the previous year. The company raised its fiscal year 2021 guidance, forecasting 17% to 19% revenue growth and non-GAAP EPS between $1.88 and $1.93.

Bruker Corporation (Nasdaq: BRKR) will announce its second quarter 2021 financial results on August 2, 2021, after market close. A conference call and webcast will take place at 4:30 p.m. ET to discuss the results and current business trends. Investors can access the webcast via the company's investor relations page or by telephone. Pre-registration for quicker access to the call is available. A replay of the conference call will be accessible until September 2, 2021. Bruker focuses on scientific instruments and solutions enhancing research across various applications.

Bruker Corporation (Nasdaq: BRKR) launched a new VIP-HESI ion source at the virtual 4D-Metabolomics™ eXceed Symposium, enhancing sensitivity gains by up to 16-fold for various small molecule applications. The VIP-HESI can be integrated with the timsTOF Pro 2 platform, improving quantitative analyses in diverse fields such as food and environmental safety. Bruker also introduced METLIN-4D, a CCS library with over 10,000 reference compounds, and CCS-Predict Pro, an algorithm for predicting CCS values, enhancing bioinformatics capabilities. The updates aim to streamline and increase the accuracy of 4D-Metabolomics and 4D-Lipidomics.

Bruker Corporation (Nasdaq: BRKR) held its Virtual Investor Day, outlining strategies and Project Accelerate 2.0 initiatives aimed at growth in proteomics and spatial biology. For FY 2021, the company anticipates revenue growth of 16% to 18%, driven by a 3% foreign currency tailwind. Non-GAAP EPS is projected between $1.84 and $1.89, up 36% to 40% year-over-year. Additionally, Bruker aims for revenues of $2.7 to $3.0 billion by FY 2024, with operating margins between 20.7% and 21.5%, showcasing long-term growth potential.